Eric Dobmeier is a biotechnology executive and board member with 25 years of leadership experience. They currently serve as a Venture Partner at Samsara Biocapital and hold multiple board positions at various biotechnology companies, including roles at IntegerBio, Janux Therapeutics, Bluejay Therapeutics, and Abdera Therapeutics. Eric has raised over $2 billion in equity financings and over $500 million through partnering deals while significantly contributing to the growth of companies specializing in novel therapeutics for cancer, autoimmune, and kidney diseases. Previously, as Chief Operating Officer at Seagen, Eric played a key role in the company’s expansion from 60 to 1,200 employees and its transition to a commercial stage. Eric's educational background includes a Bachelor of Arts in History from Princeton University and a Juris Doctor from the University of California, Berkeley - School of Law.
This person is not in any teams
This person is not in any offices